Gilead Sciences, Inc. (NASDAQ:GILD) Shares Sold by Blair William & Co. IL

Blair William & Co. IL cut its stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 13.8% during the 1st quarter, according to its most recent filing with the SEC. The institutional investor owned 804,257 shares of the biopharmaceutical company’s stock after selling 128,459 shares during the period. Blair William & Co. IL’s holdings in Gilead Sciences were worth $60,126,000 at the end of the most recent reporting period.

A number of other institutional investors also recently added to or reduced their stakes in the stock. Capital Research Global Investors lifted its position in Gilead Sciences by 10.9% during the 4th quarter. Capital Research Global Investors now owns 85,132,885 shares of the biopharmaceutical company’s stock worth $5,531,935,000 after acquiring an additional 8,343,863 shares in the last quarter. State Street Corp raised its position in shares of Gilead Sciences by 1.2% in the 4th quarter. State Street Corp now owns 58,068,763 shares of the biopharmaceutical company’s stock valued at $3,773,308,000 after purchasing an additional 686,663 shares in the last quarter. Bank of New York Mellon Corp raised its position in shares of Gilead Sciences by 3.1% in the 4th quarter. Bank of New York Mellon Corp now owns 29,067,984 shares of the biopharmaceutical company’s stock valued at $1,888,838,000 after purchasing an additional 870,944 shares in the last quarter. Geode Capital Management LLC raised its position in shares of Gilead Sciences by 2.9% in the 4th quarter. Geode Capital Management LLC now owns 19,224,037 shares of the biopharmaceutical company’s stock valued at $1,246,933,000 after purchasing an additional 535,813 shares in the last quarter. Finally, Renaissance Technologies LLC raised its position in shares of Gilead Sciences by 15.1% in the 4th quarter. Renaissance Technologies LLC now owns 16,962,944 shares of the biopharmaceutical company’s stock valued at $1,102,252,000 after purchasing an additional 2,228,686 shares in the last quarter. 77.34% of the stock is currently owned by hedge funds and other institutional investors.

In other news, EVP Brett A. Pletcher sold 10,441 shares of the company’s stock in a transaction on Monday, March 2nd. The stock was sold at an average price of $70.88, for a total transaction of $740,058.08. Following the completion of the sale, the executive vice president now directly owns 25,085 shares of the company’s stock, valued at $1,778,024.80. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, Director John Francis Cogan sold 2,413 shares of the company’s stock in a transaction on Monday, March 9th. The shares were sold at an average price of $77.97, for a total value of $188,141.61. Following the sale, the director now directly owns 57,273 shares of the company’s stock, valued at $4,465,575.81. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 60,585 shares of company stock valued at $4,671,283. 0.13% of the stock is currently owned by company insiders.

GILD has been the subject of a number of research analyst reports. Oppenheimer reiterated a “buy” rating on shares of Gilead Sciences in a report on Monday, May 18th. Wells Fargo & Co reiterated a “hold” rating and issued a $84.00 price target on shares of Gilead Sciences in a report on Friday, May 1st. Robert W. Baird reiterated a “hold” rating and issued a $75.00 price target on shares of Gilead Sciences in a report on Thursday. BMO Capital Markets downgraded Gilead Sciences from an “outperform” rating to a “market perform” rating and set a $79.00 price target for the company. in a report on Monday, April 20th. Finally, Cowen reiterated a “buy” rating and issued a $80.00 price target on shares of Gilead Sciences in a report on Monday, April 13th. Seven equities research analysts have rated the stock with a sell rating, fifteen have assigned a hold rating and nine have issued a buy rating to the stock. Gilead Sciences presently has a consensus rating of “Hold” and an average price target of $78.15.

Shares of Gilead Sciences stock traded down $0.16 during trading on Friday, hitting $73.34. The stock had a trading volume of 6,157,451 shares, compared to its average volume of 19,139,120. The company has a debt-to-equity ratio of 1.00, a current ratio of 3.04 and a quick ratio of 2.92. The firm has a market cap of $92.20 billion, a P/E ratio of 18.85, a PEG ratio of 3.14 and a beta of 0.72. The business has a fifty day moving average of $77.78 and a two-hundred day moving average of $70.16. Gilead Sciences, Inc. has a fifty-two week low of $60.89 and a fifty-two week high of $85.97.

Gilead Sciences (NASDAQ:GILD) last announced its earnings results on Thursday, April 30th. The biopharmaceutical company reported $1.68 EPS for the quarter, beating the consensus estimate of $1.57 by $0.11. Gilead Sciences had a return on equity of 35.44% and a net margin of 21.84%. The business had revenue of $5.55 billion during the quarter, compared to the consensus estimate of $5.44 billion. During the same period in the prior year, the business posted $1.67 earnings per share. Gilead Sciences’s revenue was up 5.1% compared to the same quarter last year. As a group, research analysts forecast that Gilead Sciences, Inc. will post 6.34 earnings per share for the current year.

The business also recently announced a quarterly dividend, which will be paid on Monday, June 29th. Stockholders of record on Friday, June 12th will be issued a dividend of $0.68 per share. This represents a $2.72 annualized dividend and a dividend yield of 3.71%. The ex-dividend date is Thursday, June 11th. Gilead Sciences’s dividend payout ratio is 44.30%.

About Gilead Sciences

Gilead Sciences, Inc, a research-based biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical needs in the United States, Europe, and internationally. The company's products include Biktarvy, Descovy, Odefsey, Genvoya, Stribild, Complera/Eviplera, Atripla, and Truvada for the treatment of human immunodeficiency virus (HIV) infection in adults; and Vosevi, Vemlidy, Epclusa, Harvoni, and Viread products for treating liver diseases.

Recommended Story: Bull Market

Want to see what other hedge funds are holding GILD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Gilead Sciences, Inc. (NASDAQ:GILD).

Institutional Ownership by Quarter for Gilead Sciences (NASDAQ:GILD)

Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.